Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Hindustan Copper Reports 9% Rise in MIC Output for FY26
• SAIL Shares Slip 0.91% as CMD Amarendu Prakash Steps Down
• Bosch Jumps 12% in Two Sessions on E-Mobility JV
• Latent View Analytics Shares Skyrocket 20% on Deal with Healtheon AI 
• Ola Electric Shares Jump 9% on Roadster X+ Price Cut

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.